內部人士可能會獲得普通股東無法獲得的可觀財務利益。
擬議的交易可能包含限制更優競爭報價的條款。
鼓勵股東與本公司聯繫，討論他們的權利和選擇，且無需支付任何費用或承擔任何義務。我們將以風險代理的方式處理任何事務，您無需承擔我們的法律費用或開支。
, /PRNewswire/ -- Halper Sadeh LLC，一家投資者權益法律事務所，正在調查以下公司是否可能違反聯邦證券法和/或對股東的信託責任：
Select Medical Holdings Corporation (NYSE: SEM) 以每股 16.50 美元的現金出售給由 Select Medical 高管和董事領導的財團。如果您是 Select Medical 的股東， 請點擊這裏瞭解您的權利和選擇 。
XOMA Royalty Corporation (NASDAQ: XOMA) 以每股 39.00 美元的價格出售給 Ligand Pharmaceuticals Incorporated。如果您是 XOMA 的股東， 請點擊這裏瞭解您的權利和選擇 。
Soleno Therapeutics, Inc. (NASDAQ: SLNO) 以每股 53.00 美元的現金出售給 Neurocrine Biosciences。如果您是 Soleno 的股東， 請點擊這裏瞭解您的法律權利和選擇。
KORE Group Holdings, Inc. (NYSE: KORE) 以每股 9.25 美元的價格出售給 Searchlight Capital Partners, L.P.和 Abry Partners。如果您是 KORE 的股東， 請點擊這裏瞭解您的權利和選擇 。
代表股東，Halper Sadeh LLC 可能尋求增加對價、額外披露和信息，或其他救濟和利益。
Halper Sadeh LLC 代表全球受證券欺詐和公司不當行為影響的投資者。我們的律師在實施公司改革和為受欺詐投資者追回數百萬美元方面發揮了重要作用。
律師廣告。以往的結果並不保證類似的結果。
聯繫信息：
Halper Sadeh LLC
Daniel Sadeh, Esq.
Zachary Halper, Esq.
世界貿易中心一號
85 層
紐約，NY 10007
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com
來源 Halper Sadeh LLP
<img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTA4Jk5ld3NJdGVtSWQ9Tlk1NTM1MyZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MDgxNzU3UFJfTkVXU19VU1BSX19fX19OWTU1MzUz?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTA4Jk5ld3NJdGVtSWQ9Tlk1NTM1MyZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MDgxNzU3UFJfTkVXU19VU1BSX19fX19OWTU1MzUz"/>

Soleno治療

KORE

Select醫藥控股

標記臨牀研究

Halper Sadeh LLC 正在調查 Select Medical Holdings Corporation、XOMA Royalty Corporation、Soleno Therapeutics 和 KORE Group Holdings 是否存在潛在的聯邦證券法違規和違反信託責任的行為。該公司擔心內部人士可能會在普通股東的利益受損的情況下獲得財務利益。鼓勵股東聯繫該公司，討論他們在這些公司擬議出售方面的權利和選擇。Halper Sadeh LLC 旨在為股東爭取更高的對價和其他利益

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
<div class="lb-trans">內部人士可能會獲得普通股東無法獲得的可觀財務利益。
</div>The proposed transactions may contain terms that could limit superior competing offers.
<div class="lb-trans">擬議的交易可能包含限制更優競爭報價的條款。
</div>Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
<div class="lb-trans">鼓勵股東與本公司聯繫，討論他們的權利和選擇，且無需支付任何費用或承擔任何義務。我們將以風險代理的方式處理任何事務，您無需承擔我們的法律費用或開支。
</div>, /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
<div class="lb-trans">, /PRNewswire/ -- Halper Sadeh LLC，一家投資者權益法律事務所，正在調查以下公司是否可能違反聯邦證券法和/或對股東的信託責任：
</div>Select Medical Holdings Corporation (NYSE: SEM)'s sale to a consortium led by Select Medical executives and directors for $16.50 in cash per share. If you are a Select Medical shareholder, click here to learn more about your rights and options .
<div class="lb-trans">Select Medical Holdings Corporation (NYSE: SEM) 以每股 16.50 美元的現金出售給由 Select Medical 高管和董事領導的財團。如果您是 Select Medical 的股東， 請點擊這裏瞭解您的權利和選擇 。
</div>XOMA Royalty Corporation (NASDAQ: XOMA)'s sale to Ligand Pharmaceuticals Incorporated for $39.00 per share. If you are a XOMA shareholder, click here to learn more about your rights and options .
<div class="lb-trans">XOMA Royalty Corporation (NASDAQ: XOMA) 以每股 39.00 美元的價格出售給 Ligand Pharmaceuticals Incorporated。如果您是 XOMA 的股東， 請點擊這裏瞭解您的權利和選擇 。
</div>Soleno Therapeutics, Inc. (NASDAQ: SLNO)'s sale to Neurocrine Biosciences for $53.00 per share in cash. If you are a Soleno shareholder, click here to learn more about your legal rights and options.
<div class="lb-trans">Soleno Therapeutics, Inc. (NASDAQ: SLNO) 以每股 53.00 美元的現金出售給 Neurocrine Biosciences。如果您是 Soleno 的股東， 請點擊這裏瞭解您的法律權利和選擇。
</div>KORE Group Holdings, Inc. (NYSE: KORE)'s sale to Searchlight Capital Partners, L.P. and Abry Partners for $9.25 per share. If you are a KORE shareholder, click here to learn more about your rights and options .
<div class="lb-trans">KORE Group Holdings, Inc. (NYSE: KORE) 以每股 9.25 美元的價格出售給 Searchlight Capital Partners, L.P.和 Abry Partners。如果您是 KORE 的股東， 請點擊這裏瞭解您的權利和選擇 。
</div>On behalf of shareholders, Halper Sadeh LLC may seek increased consideration, additional disclosures and information, or other relief and benefits.
<div class="lb-trans">代表股東，Halper Sadeh LLC 可能尋求增加對價、額外披露和信息，或其他救濟和利益。
</div>Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
<div class="lb-trans">Halper Sadeh LLC 代表全球受證券欺詐和公司不當行為影響的投資者。我們的律師在實施公司改革和為受欺詐投資者追回數百萬美元方面發揮了重要作用。
</div>Attorney Advertising. Prior results do not guarantee a similar outcome.
<div class="lb-trans">律師廣告。以往的結果並不保證類似的結果。
</div>Contact Information:
<div class="lb-trans">聯繫信息：
</div>Halper Sadeh LLC
<div class="lb-trans">Halper Sadeh LLC
</div>Daniel Sadeh, Esq.
<div class="lb-trans">Daniel Sadeh, Esq.
</div>Zachary Halper, Esq.
<div class="lb-trans">Zachary Halper, Esq.
</div>One World Trade Center
<div class="lb-trans">世界貿易中心一號
</div>85th Floor
<div class="lb-trans">85 層
</div>New York, NY 10007
<div class="lb-trans">紐約，NY 10007
</div>(212) 763-0060
<div class="lb-trans">(212) 763-0060
</div>[email protected]
<div class="lb-trans">[email protected]
</div>[email protected]
<div class="lb-trans">[email protected]
</div>https://www.halpersadeh.com
<div class="lb-trans">https://www.halpersadeh.com
</div>SOURCE Halper Sadeh LLP
<div class="lb-trans">來源 Halper Sadeh LLP
</div><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTA4Jk5ld3NJdGVtSWQ9Tlk1NTM1MyZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MDgxNzU3UFJfTkVXU19VU1BSX19fX19OWTU1MzUz" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=NY55353&amp;Transmission_Id=202605081757PR_NEWS_USPR_____NY55353&amp;DateId=20260508"/>

Select 醫藥控股、XOMA Royalty、Soleno 治療、KORE 是否為其股東爭取到了公平的交易？